Postcovid Syndrome and Chronic Heart Failure: Current Issues
https://doi.org/10.31550/1727-2378-2022-21-6-13-18
Abstract
Objective of the Review: To consider the pathogenetic relationship of COVID-19 and chronic heart failure, the concept of “postcovid syndrome”, the peculiarities of management of this group of patients.
Key points. Chronic heart failure is a predictor of an unfavorable outcome in patients with COVID-19. Angiotensin converting enzyme 2 is involved in the penetration of viral particles into the cell. Direct viral damage to cardiomyocytes is not excluded, cardiotoxic effects of antiviral therapy are possible. The consequences of COVID-19 are manifested by arrhythmia, myocarditis and pericarditis, cardiomyopathy. Corticosteroids can lead to decompensation of heart failure. The use of renin-angiotensin-aldosterone system inhibitors and β-blockers is associated with lower mortality.
Conclusion. Chronic heart failure in combination with postcovid syndrome requires carefully developed patient management tactics and rehabilitation measures.
About the Authors
D. Yu. Gamayunov
Federal State Budgetary Educational Institution of Higher Education “Irkutsk State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
1 Krasnoe Vosstanie Str., Irkutsk, 664003
A. N. Kalyagin
Federal State Budgetary Educational Institution of Higher Education “Irkutsk State Medical University” of the Ministry of Healthcare of the Russian Federation; Regional State Budgetary Institution of Health “Irkutsk Municipal Clinical Hospital No. 1”
Russian Federation
Russian Federation
1 Krasnoe Vosstanie Str., Irkutsk, 664003
118 Baykalskaya Str., Irkutsk, 664046
G. M. Sinkova
Federal State Budgetary Educational Institution of Higher Education “Irkutsk State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
1 Krasnoe Vosstanie Str., Irkutsk, 664003
O. V. Ryzhkova
Federal State Budgetary Educational Institution of Higher Education “Irkutsk State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
1 Krasnoe Vosstanie Str., Irkutsk, 664003
Yu. O. Varavko
Federal State Budgetary Educational Institution of Higher Education “Irkutsk State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
1 Krasnoe Vosstanie Str., Irkutsk, 664003
References
1. Ponsford M.J., Ward T.J.C., Stoneham S.M., Dallimore C.M. et al. A systematic review and meta-analysis of inpatient mortality associated with nosocomial and community COVID-19 exposes the vulnerability of immunosuppressed adults. Front. Immunol. 2021; 12: 744696. DOI: 10.3389/fimmu.2021.744696
2. Taylor C.A., Patel K., Pham H., Whitaker M. et al. Severity of disease among adults hospitalized with laboratory-confirmed COVID-19 before and during the period of SARS-CoV-2 B.1.617.2 (delta) predominance — COVID-NET, 14 states, January — August 2021. Morb. Mortal Wkly Rep. 2021; 70(43): 1513–19. DOI: 10.15585/mmwr.mm7043e1
3. Rassokhin V.V., Samarina A.V., Belyakov N.A., Trofimova T.N. et al. Epidemiology, clinical picture, diagnostics, assessment of the severity of the disease COVID-19. HIV Infection and Immunosuppressive Disorders. 2020; 12(2): 7–30 (in Russian). DOI: 10.22328/2077-9828-2020-12-2-7-30
4. Bubnova M.G., Aronov D.M. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. Pulmonologiya. 2020; 30(5): 688–99 (in Russian). DOI: 10.18093/0869-0189-2020-30-5-688-699
5. Javanmardi F., Keshavarzi A., Akbari A., Emami A. et al. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020; 15(10): e0241265. DOI: 10.1371/journal.pone.0241265
6. Zhou F., Yu T., Du R., Fan G. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054–62. DOI: 10.1016/S0140-6736(20)30566-3
7. Huang C., Wang Y., Li X., Ren L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5
8. Bazdyrev E.D. Coronavirus disease: a global problem of the 21st century. Complex Issues of Cardiovascular Diseases. 2020; 9(2): 6–16 (in Russian). DOI: 10.17802/2306-1278-2020-9-2-6-16
9. Beltrami M., Bartolini S., Milli M., Palazzuoli A. The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease. Rev. Cardiovasc. Med. 2021; 22(3): 677–90. DOI: 10.31083/j.rcm2203077
10. Goyal P., Reshetnyak E., Khan S., Musse M. et al. Clinical characteristics and outcomes of adults with a history of heart failure hospitalized for COVID-19. Circ. Heart Fail. 2021; 14(9): e008354. DOI: 10.1161/CIRCHEARTFAILURE.121.008354
11. Tempany M., Leonard A., Prior A.R., Boran G. et al. The potential impact of post-COVID symptoms in the healthcare sector. Occup. Med. 2021; 71(6–7): 284–9. DOI: 10.1093/occmed/kqab109
12. Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad. Med. J. 2021; 97(1147): 312–20. DOI: 10.1136/postgradmedj-2020-138577
13. Litvinov A.S., Savin A.V., Kuhtina A.A. Long-term prospects of extrapulmonary persistence of SARS-COV-2 coronavirus. Medicine. 2020; 8(1): 51–73 (in Russian). DOI: 10.29234/2308-9113-2020-8-1-51-73
14. Nakou E., De Garate E., Liang K., Williams M. et al. Imaging findings of COVID-19-related cardiovascular complications. Card. Electrophysiol. Clin. 2022; 14(1): 79–93. DOI: 10.1016/j.ccep.2021.10.008
15. Guo T., Fan Y., Chen M., Wu X. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7): 811–18. DOI: 10.1001/jamacardio.2020.1017
16. Giustino G., Croft L.B., Oates C.P., Rahman K. et al. Takotsubo cardiomyopathy in COVID-19. J. Am. Coll. Cardiol. 2020; 76(5): 628–29. DOI: 10.1016/j.jacc.2020.05.068
17. Shah R.M., Shah M., Shah S., Li A. et al. Takotsubo syndrome and COVID-19: associations and implications. Curr. Probl. Cardiol. 2021; 46(3): 100763. DOI: 10.1016/j.cpcardiol.2020.100763
18. Kanorskii S.G. Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kuban Scientific Medical Bulletin. 2021; 28(6): 90–116. (in Russian). DOI: 10.25207/1608-6228-2021-28-6-90-116
19. Belyakov N.A., Trofimova T.N., Simakina O.E., Rassokhin V.V. The dynamics of the COVID-19 pandemic and formation of the postcovid period in Russia. HIV Infection and Immunosuppressive Disorders. 2021; 13(2): 7–19. (in Russian). DOI: 10.22328/2077-9828-2021-13-2-7-19
20. Thomas P., Baldwin C., Beach L., Bissett B. et al. Physiotherapy management for COVID-19 in the acute hospital setting and beyond: an update to clinical practice recommendations. J. Physiother. 2022; 68(1): 8–25. DOI: 10.1016/j.jphys.2021.12.012
21. Amirov N.B., Davletshina E.I., Vasilyeva A.G., Fatykhov R.G. Postcovid syndrome: multisystem “deficits”. Bulletin of Contemporary Clinical Medicine. 2021; 14(6): 94–104. (in Russian). DOI: 10.20969/VSKM.2021.14(6).94-104
22. Dotan A., Shoenfeld Y. Post-COVID syndrome: the aftershock of SARS-CoV-2. Int. J. Infect. Dis. 2022; 114: 233–5. DOI: 10.1016/j.ijid.2021.11.020
23. Parums D.V. Editorial: multisystem inflammatory syndrome in adults (MIS-A) and the spectrum of COVID-19. Med. Sci. Monitor. 2021; 27: e935005. DOI: 10.12659/MSM.935005
24. Moreno-Pérez O., Merino E., Leon-Ramirez J.M., Andres M. et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J. Infect. 2021; 82(3): 378–83. DOI: 10.1016/j.jinf.2021.01.004
25. Becker J.H., Lin J.J., Doernberg M., Stone K. et al. Assessment of cognitive function in patients after COVID-19 infection. JAMA Network Open. 2021; 4(10): e2130645. DOI: 10.1001/jamanetworkopen.2021.30645
26. Kazarina A.P., Selikhanova V.M. Post-covid depression. Literature review. Science and Healthcare. 2021; 23(3): 16–23. (in Russian). DOI: 10.34689/SH.2021.23.3.002
27. Taquet M., Luciano S., Geddes J.R., Harrison P.J. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021; 8(2): 130–40. DOI: 10.1016/S2215-0366(20)30462-4
28. Luo M., Guo L., Yu M., Jiang W. et al. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public — a systematic review and meta-analysis. Psychiatry Res. 2020; 291: 113190. DOI: 10.1016/j.psychres.2020.113190
29. Carfi A., Bernabei R., Landi F.; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324(6): 603–5. DOI: 10.1001/jama.2020.12603
30. Huang C., Huang L., Wang Y., Li X. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397(10270): 220–32. DOI: 10.1016/S0140-6736(20)32656-8
31. Nehme M., Braillard O., Chappuis F., Courvoisier D.S. et al. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. Ann. Intern. Med. 2021; 174(9): 1252–60. DOI: 10.7326/M21-0878
32. Zhao Y.M., Shang Y.M., Song W.B., Li Q.Q. et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020; 25: 100463. DOI: 10.1016/j.eclinm.2020.100463
33. Wells A.U., Devaraj A., Desai S.R. Interstitial lung disease after COVID-19 infection: a catalog of uncertainties. Radiology. 2021; 299(1): 216–18. DOI: 10.1148/radiol.2021204482
34. Middeldorp S., Coppens M., van Haaps T.F., Foppen M. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 2020; 18(8): 1995–2002. DOI: 10.1111/jth.14888
35. Graham E.L., Clark J.R., Orban Z.S., Lim P.H. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”. Ann. Clin. Transl. Neurol. 2021; 8(5): 1073–85. DOI: 10.1002/acn3.51350
36. Weng J., Li Y., Li J., Shen L. et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol. Hepatol. 2021; 6(5): 344–6. DOI: 10.1016/S2468-1253(21)00076-5
37. Bhatia K.S, van Gaal W., Kritharides L., Chow C.K. et al. The incidence of cardiac complications in patients hospitalised with COVID-19 in Australia: the AUS-COVID study. Med. J. Aust. 2021; 215(6): 279. DOI: 10.5694/mja2.51225
38. Richter D., Guasti L., Koehler F., Squizzato A. et al. Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice. ESC Heart Fail. 2021; 8(5): 3483–94. DOI: 10.1002/ehf2.13466
39. Vaduganathan M., Vardeny O., Michel T., McMurray J.J.V. et al. Reninangiotensin-aldosterone system inhibitors in patients with COVID-19. New Engl. J. Med. 2020; 382(17): 1653–9. DOI: 10.1056/NEJMsr2005760
40. Pérez-Belmonte L.M., Sanz-Cánovas J., Salinas A., Fornie I.S. et al. SEMI-COVID-19 Network. Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study. Intern. Emerg. Med. 2021; 16(8): 2301–5. DOI: 10.1007/s11739-021-02843-4
41. Terlecki M., Wojciechowska W., Klocek M., Olszanecka A. et al. Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland. Kardiol. Pol. (Polish Heart Journal). 2021; 79(7–8): 773–80. DOI: 10.33963/KP.15990
42. Podzolkov V.I., Tarzimanova A.I. The importance of antihypertensive and lipid-lowering therapy in the treatment of patients with a new coronavirus infection COVID-19. Rational Pharmacotherapy in Cardiology. 2021; 17(2): 310–14. (in Russian). DOI: 10.20996/1819-6446-2021-03-01
Review
For citations:
Gamayunov D.Yu., Kalyagin A.N., Sinkova G.M., Ryzhkova O.V., Varavko Yu.O. Postcovid Syndrome and Chronic Heart Failure: Current Issues. Title. 2022;21(6):13-18. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-6-13-18
Views:
22
Email this article 